Estamos no ar no ! Saiba mais

Neuraxis

NRXS

Valor de mercado US$ 96,7 mi

7,70 USD

-0,04

0,52%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

7,70

0,00

0%

1 dia

-0,52%

5 dias

12,24%

1 mês

10,95%

3 meses

13,57%

6 meses

4,62%

No acumulado do ano

72,65%

1 ano

145,22%

5 anos

28,33%

10 anos

28,33%

Sobre: Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Funcionários: 24

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 27,3%

Neutro 72,7%

Negativo 0%

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

Total national coverage footprint for PENFS increases to over 147 million covered lives Total national coverage footprint for PENFS increases to over 147 million covered lives

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer.

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”).

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

Zacks Investment Research

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Zacks Investment Research

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

KODK and NRXS are worth watching for their growth.

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

Zacks Investment Research

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis Expands Payer Coverage with New Policies

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.

NeurAxis Expands Payer Coverage with New Policies

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™